[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1248135A1 - 用於治療癌症的聯合方法 - Google Patents

用於治療癌症的聯合方法

Info

Publication number
HK1248135A1
HK1248135A1 HK18107775.6A HK18107775A HK1248135A1 HK 1248135 A1 HK1248135 A1 HK 1248135A1 HK 18107775 A HK18107775 A HK 18107775A HK 1248135 A1 HK1248135 A1 HK 1248135A1
Authority
HK
Hong Kong
Prior art keywords
treating cancer
combination method
combination
cancer
treating
Prior art date
Application number
HK18107775.6A
Other languages
English (en)
Inventor
Takahiko Seki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1248135A1 publication Critical patent/HK1248135A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK18107775.6A 2015-02-20 2018-06-15 用於治療癌症的聯合方法 HK1248135A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015032201 2015-02-20
PCT/JP2016/054822 WO2016133194A1 (ja) 2015-02-20 2016-02-19 がんの併用治療法

Publications (1)

Publication Number Publication Date
HK1248135A1 true HK1248135A1 (zh) 2018-10-12

Family

ID=56692186

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107775.6A HK1248135A1 (zh) 2015-02-20 2018-06-15 用於治療癌症的聯合方法

Country Status (10)

Country Link
US (1) US10716790B2 (zh)
EP (1) EP3260119B1 (zh)
JP (2) JP6564449B2 (zh)
KR (1) KR102595395B1 (zh)
CN (1) CN107427501B (zh)
CA (1) CA2976752C (zh)
ES (1) ES2968789T3 (zh)
HK (1) HK1248135A1 (zh)
TW (1) TWI711452B (zh)
WO (1) WO2016133194A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180296547A1 (en) * 2015-10-23 2018-10-18 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
KR20210038366A (ko) * 2019-09-30 2021-04-07 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2022027237A1 (zh) * 2020-08-04 2022-02-10 宜昌市第一人民医院（三峡大学人民医院） 奎扎替尼作为程序性坏死抑制剂的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT959132E (pt) 1996-10-18 2006-12-29 Takara Bio Inc Ácido nucleico que codifica um receptor do tipo de proteína cinase
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
SG155941A1 (en) 2004-09-22 2009-10-29 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
EA014445B1 (ru) * 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
ATE495176T1 (de) 2006-03-13 2011-01-15 Hoffmann La Roche Spiroindolinon-derivate
KR101549364B1 (ko) 2006-03-17 2015-09-01 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
US20090233905A1 (en) 2006-04-05 2009-09-17 Gregory Peter Burke Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
WO2008036168A2 (en) 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
CN101516366B (zh) 2006-09-21 2012-05-30 霍夫曼-拉罗奇有限公司 作为抗癌剂的羟吲哚衍生物
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CA2680122A1 (en) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
WO2008119741A2 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
PL2201018T3 (pl) 2007-09-19 2016-11-30 STAŁE POSTACIE ZAWIERAJĄCE N-(5-TERT-BUTYLOIZOKSAZOL-3-ILO)-N'-{4--[7-(2-MORFOLIN-4-YLOETOKSY)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-ILO]FENYLO}MOCZNIK, ICH KOMPOZYCJE ORAZ ICH ZASTOSOWANIA
US7968543B2 (en) 2007-11-08 2011-06-28 Ambit Biosciences Corporation Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
MY160424A (en) 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
US20100190814A1 (en) 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CA2755976C (en) * 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
WO2010132787A1 (en) 2009-05-14 2010-11-18 Ambit Biosciences Corporation Methods of treating proliferative diseases
EP2563360A4 (en) 2010-04-09 2015-12-16 Univ Michigan BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN DISEASE TREATMENT
JP5792279B2 (ja) 2011-03-10 2015-10-07 第一三共株式会社 ジスピロピロリジン誘導体
AU2012253339B2 (en) 2011-05-11 2016-03-31 Sanofi Spiro-oxindole MDM2 antagonists
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
SI2880447T1 (sl) 2012-07-31 2019-09-30 Novartis Ag Označevalci povezani z občutljivostjo na inhibitorje humanega dvominutnega 2 proteina (mdm2)
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
JP6461126B2 (ja) 2013-07-03 2019-01-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｍｄｍ２アンタゴニストを用いた患者のがん治療法をパーソナライズするためのｍｒｎａベースの遺伝子発現
SI3068393T1 (sl) 2013-11-11 2022-11-30 Amgen Inc. Kombinirana terapija, ki vključuje zaviralec MDM2 in eno ali več dodatnih farmacevtskih učinkovin za zdravljenje različnih vrst raka

Also Published As

Publication number Publication date
EP3260119A4 (en) 2018-08-08
JPWO2016133194A1 (ja) 2017-11-09
EP3260119B1 (en) 2023-11-15
EP3260119A1 (en) 2017-12-27
ES2968789T3 (es) 2024-05-14
TW201636020A (zh) 2016-10-16
CA2976752A1 (en) 2016-08-25
US20170216302A1 (en) 2017-08-03
CN107427501B (zh) 2023-12-01
TWI711452B (zh) 2020-12-01
KR20170123602A (ko) 2017-11-08
JP2019108390A (ja) 2019-07-04
CN107427501A (zh) 2017-12-01
JP6564449B2 (ja) 2019-08-21
WO2016133194A1 (ja) 2016-08-25
KR102595395B1 (ko) 2023-10-27
US10716790B2 (en) 2020-07-21
CA2976752C (en) 2019-12-17

Similar Documents

Publication Publication Date Title
HK1251407A1 (zh) 治療癌症的方法
IL304252A (en) Cancer treatment methods
ZA201706616B (en) Method for treating cancer
IL289947A (en) A method for treating cancer
IL257691A (en) A method for treating cancer
RS63561B1 (sr) Kompozicija za lečenje raka
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1250944A1 (zh) 用於治療癌症的方法
HK1248135A1 (zh) 用於治療癌症的聯合方法
IL255079A0 (en) Methods of treating lung cancer
HK1250942A1 (zh) 用於治療癌症的方法
HK1250943A1 (zh) 用於治療癌症的方法
EP3247376A4 (en) Method for treating cancer
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (zh) 用於治療腫瘤的方法